MARKET

BIO

BIO

Bio Rad Labs Inc
NYSE
280.07
-10.79
-3.71%
Opening 15:02 04/18 EDT
OPEN
276.60
PREV CLOSE
290.86
HIGH
286.65
LOW
268.92
VOLUME
280.21K
TURNOVER
0
52 WEEK HIGH
494.05
52 WEEK LOW
261.59
MARKET CAP
7.99B
P/E (TTM)
-12.8358
1D
5D
1M
3M
1Y
5Y
Commit To Purchase Bio-Rad Laboratories At $185, Earn 1.3% Annualized Using Options
NASDAQ · 1d ago
Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition
NASDAQ · 2d ago
Weekly Report: what happened at BIO last week (0408-0412)?
Weekly Report · 3d ago
Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker
Bio-Rad is a "picks and shovels" company in the life sciences industry but lacks standout growth, margins, or returns. The company saw double-digit declines in its Life Sciences segment in the last two quarters. Bio-Rad's holdings in Sartorius bring significant value to the company, but it's hard to love the stock on its own.
Seeking Alpha · 5d ago
Oncocyte stock rallies 90% post-market on Bio-Rad partnership
Oncocyte announced a partnership with Bio-Rad for the global launch of its GraftAssure assay for organ transplant monitoring. The product is slated to be launched in Q2 to select academic transplant centers in the US and EU. Oncocyte stock rallies 90% post-market on Bio- Rad partnership.
Seeking Alpha · 04/11 22:15
Oncocyte, Bio-Rad Partner on Global Launch of Transplant Assay
Oncocyte and Bio-Rad agree to a partnership agreement to commercialize the research use only GraftAssure assay. The product is expected to launch in the second quarter to a select group of academic transplant centers in the U.S. And EU. The companies will co-market the assay in the US and Germany. Oncocyte uses donor-derived cell-free DNA to assess organ health.
Dow Jones · 04/11 22:11
BUZZ-OncoCyte jumps on partnership with Bio-Rad
OncoCyte shares rise 93.3% to $5.73 in extended trading. Company announces partnership with Bio-Rad for blood-based organ transplantation monitoring test GraftAssure. Shares of diagnostics company up 18.6% year-to-date.
Reuters · 04/11 22:09
Oncocyte Announces Partnership Agreement With Bio-Rad Laboratories On Global Launch Of Transplant Assay; Bio-Rad Expects To Make Equity Investment In Support Of Deal
New product expected to launch in Q2 2024 to a select group of academic transplant centers in the US and EU. Bio-Rad and Oncocyte will co-market the assay in the U.S. And Germany. The company has been granted exclusive global distribution and commercial rights.
Benzinga · 04/11 21:32
More
About BIO
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Its Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes and food testing regimes. The Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are primarily sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Webull offers Bio Rad Laboratories Inc stock information, including NYSE: BIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIO stock methods without spending real money on the virtual paper trading platform.